Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
04-01-02 Anxiolytics
CSM advice: Use of benzodiazepines for relief of anxiety - see BNF
Anxiolytics should be used at the lowest possible dose for the shortest possible time.
| Pregabalin |
|
Formulary
|
Capsules |
 MHRA: Pregabalin (Lyrica): findings of safety study on risks during pregnancy MHRA: Pregabalin (Lyrica): reports of severe respiratory depression |
|
Links
- MHRA Drug Safety Update April 2016: Meprobamate: licence to be cancelled
- MHRA Drug Safety Update April 2022: Pregabalin (Lyrica): findings of safety study on risks during pregnancy
- MHRA Drug Safety Update Feb 2021: Pregabalin (Lyrica): reports of severe respiratory depression
- MHRA: Pregabalin (Lyrica): findings of safety study on risks during pregnancy
- MHRA: Pregabalin (Lyrica): reports of severe respiratory depression
- NICE CG113: Generalised anxiety disorder and panic disorder in adults: management
- NICE NG163: COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community